#Singapore #HistoIndex #FibroSIGHT Plus #qFibrosis

HistoIndex Unveils FibroSIGHT™ Plus

HistoIndex, a leader in digital pathology, has recently announced the launch of FibroSIGHT™ Plus, an advanced tool designed for the quantitative analysis of fibrosis, specifically targeting Metabolic Dysfunction-associated Steatohepatitis (MASH). This represents a significant enhancement over the previously introduced FibroSIGHT™, as it incorporates automation in fibrosis assessment, thus providing more consistent and accurate evaluations.

The essence of FibroSIGHT™ Plus lies in its core component, qFibrosis®, an AI-driven algorithm that utilizes stain-free Second Harmonic Generation (SHG) imaging of liver biopsies impacted by MASH. This cutting-edge technology allows for the automatic quantification of multiple collagen parameters related to fibrosis, translating complex data into a singular numerical value or stage of fibrosis. Unlike traditional methods which categorize fibrosis into fixed stages, this approach offers continuous insights into disease severity, making it a vital tool for clinicians seeking to understand and track the progress of their patients’ conditions.

Yukti Choudhury, Chief Development Officer at HistoIndex, expressed excitement over this advancement, asserting that it bridges the gap between clinical trial experiences and everyday clinical applications. Clinicians like Dr. Naim Alkhouri have noted the benefits of this automated solution, particularly its potential for early interventions in MASH management by accurately detecting even minor changes in fibrosis. Traditional pathology methods often come with variability concerns due to subjective interpretations; however, FibroSIGHT™ Plus standardizes measurements across entire biopsy samples, significantly reducing inconsistencies associated with human evaluation.

In collaboration with expert pathologists, HistoIndex's qFibrosis® has shown impressive reproducibility compared to conventional scoring systems. This alignment with expert consensus not only boosts confidence in the diagnostic process but also supports tailored, data-informed treatment strategies. As Dr. Mazen Noureddin highlighted, moving away from subjective scoring to reliable, quantitative metrics is pivotal in improving clinical practice.

HistoIndex continues its mission to integrate digital pathology into routine patient care, enhancing the accuracy of MASH diagnostics. With additional innovations in the pipeline, the company remains at the forefront of transforming patient outcomes through technology.

Understanding MASH

Metabolic Dysfunction-associated Steatohepatitis (MASH) represents a concerning progression of liver disease characterized by inflammation and scarring, which can lead to severe complications, including cirrhosis and liver cancer. Historically, the gold standard for diagnosing and assessing MASH has involved pathologist evaluations of liver biopsies. However, traditional histological categories fall short in capturing the disease's complex nature. This emphasizes the growing need for more accurate methods, like those offered by HistoIndex, that leverage AI-based technologies to enhance the assessment of disease severity and treatment responses.

About HistoIndex

Founded in 2010, HistoIndex specializes in stain-free, fully automated imaging technologies for quantifying tissue fibrosis. Their innovative offerings are instrumental in accelerating clinical research and drug development processes, ultimately aiming to improve medical standards for liver disease management. With its cutting-edge approaches, HistoIndex is setting new benchmarks for fibrosis assessment, as evident in the revolutionary FibroSIGHT™ Plus.